Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:12389876rdf:typepubmed:Citationlld:pubmed
pubmed-article:12389876lifeskim:mentionsumls-concept:C0939537lld:lifeskim
pubmed-article:12389876lifeskim:mentionsumls-concept:C1332838lld:lifeskim
pubmed-article:12389876lifeskim:mentionsumls-concept:C2003905lld:lifeskim
pubmed-article:12389876pubmed:issue10lld:pubmed
pubmed-article:12389876pubmed:dateCreated2002-10-22lld:pubmed
pubmed-article:12389876pubmed:abstractTextTo review the pharmacology, pharmacokinetics, efficacy, safety, and drug-drug and drug-food interactions of imatinib and the economic considerations of imatinib in the treatment of chronic myeloid leukemia (CML).lld:pubmed
pubmed-article:12389876pubmed:languageenglld:pubmed
pubmed-article:12389876pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12389876pubmed:citationSubsetIMlld:pubmed
pubmed-article:12389876pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12389876pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12389876pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12389876pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12389876pubmed:statusMEDLINElld:pubmed
pubmed-article:12389876pubmed:monthOctlld:pubmed
pubmed-article:12389876pubmed:issn0277-0008lld:pubmed
pubmed-article:12389876pubmed:authorpubmed-author:ZarowitzBarba...lld:pubmed
pubmed-article:12389876pubmed:authorpubmed-author:PindoliaVanit...lld:pubmed
pubmed-article:12389876pubmed:issnTypePrintlld:pubmed
pubmed-article:12389876pubmed:volume22lld:pubmed
pubmed-article:12389876pubmed:ownerNLMlld:pubmed
pubmed-article:12389876pubmed:authorsCompleteYlld:pubmed
pubmed-article:12389876pubmed:pagination1249-65lld:pubmed
pubmed-article:12389876pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:12389876pubmed:meshHeadingpubmed-meshheading:12389876...lld:pubmed
pubmed-article:12389876pubmed:meshHeadingpubmed-meshheading:12389876...lld:pubmed
pubmed-article:12389876pubmed:meshHeadingpubmed-meshheading:12389876...lld:pubmed
pubmed-article:12389876pubmed:meshHeadingpubmed-meshheading:12389876...lld:pubmed
pubmed-article:12389876pubmed:meshHeadingpubmed-meshheading:12389876...lld:pubmed
pubmed-article:12389876pubmed:meshHeadingpubmed-meshheading:12389876...lld:pubmed
pubmed-article:12389876pubmed:meshHeadingpubmed-meshheading:12389876...lld:pubmed
pubmed-article:12389876pubmed:meshHeadingpubmed-meshheading:12389876...lld:pubmed
pubmed-article:12389876pubmed:meshHeadingpubmed-meshheading:12389876...lld:pubmed
pubmed-article:12389876pubmed:meshHeadingpubmed-meshheading:12389876...lld:pubmed
pubmed-article:12389876pubmed:meshHeadingpubmed-meshheading:12389876...lld:pubmed
pubmed-article:12389876pubmed:meshHeadingpubmed-meshheading:12389876...lld:pubmed
pubmed-article:12389876pubmed:meshHeadingpubmed-meshheading:12389876...lld:pubmed
pubmed-article:12389876pubmed:year2002lld:pubmed
pubmed-article:12389876pubmed:articleTitleImatinib mesylate, the first molecularly targeted gene suppressor.lld:pubmed
pubmed-article:12389876pubmed:affiliationPharmacy Care Management, Henry Ford Health System, Detroit, Michigan, USA.lld:pubmed
pubmed-article:12389876pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:12389876pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:12389876pubmed:publicationTypeReviewlld:pubmed